Trial Profile
Multicentre, double-blind, randomized, placebo-controlled, parallel-group, clinical trial to evaluates the clinical efficacy and safety of immunotherapy with purified major allergen Alt a 1 in patients with allergic rhinoconjunctivitis with or without mild to moderate asthma, sensitized the fungus Alternaria alternata [Ensayo clinico multicentrico, doble ciego, aleatorizado y controlado con placebo, en grupos paralelos, que evalua la eficacia clínica y seguridad de la inmunoterapia con el alergeno mayor purificado Alt a 1, en pacientes con rinoconjuntivitis alergica con o sin asma leve o moderada, sensibilizados al hongo Alternaria alternata]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Alternaria allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Hypersensitivity
- Focus Therapeutic Use
- 01 Apr 2017 Status changed from recruiting to completed.
- 04 Jan 2012 New trial record